Business Description
Prelude Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US74065P1012
Share Class Description:
PRLD: Ordinary SharesDescription
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.47 | |||||
| Equity-to-Asset | 0.79 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | -0.13 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -4.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 22.5 | |||||
| 3-Year EPS without NRI Growth Rate | 23.8 | |||||
| 3-Year FCF Growth Rate | 21.2 | |||||
| 3-Year Book Growth Rate | -3.8 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 66.64 | |||||
| 9-Day RSI | 62.72 | |||||
| 14-Day RSI | 56.06 | |||||
| 6-1 Month Momentum % | -75.86 | |||||
| 12-1 Month Momentum % | -77.47 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.04 | |||||
| Quick Ratio | 7.04 | |||||
| Cash Ratio | 6.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.9 | |||||
| Shareholder Yield % | -25.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -4775.4 | |||||
| Net Margin % | -4383.9 | |||||
| FCF Margin % | -3585.4 | |||||
| ROE % | -64.17 | |||||
| ROA % | -54.58 | |||||
| ROIC % | -299.39 | |||||
| ROC (Joel Greenblatt) % | -459.96 | |||||
| ROCE % | -64.95 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 29.75 | |||||
| PB Ratio | 0.42 | |||||
| Price-to-Tangible-Book | 0.42 | |||||
| EV-to-EBIT | 0.47 | |||||
| EV-to-EBITDA | 0.47 | |||||
| EV-to-Revenue | -22.42 | |||||
| EV-to-FCF | 0.63 | |||||
| Price-to-Net-Current-Asset-Value | 0.57 | |||||
| Price-to-Net-Cash | 0.58 | |||||
| Earnings Yield (Greenblatt) % | 212.77 | |||||
| FCF Yield % | -164.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PRLD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Prelude Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 3 | ||
| EPS (TTM) ($) | -1.78 | ||
| Beta | 1.51 | ||
| Volatility % | 119.78 | ||
| 14-Day RSI | 56.06 | ||
| 14-Day ATR ($) | 0.153356 | ||
| 20-Day SMA ($) | 0.994225 | ||
| 12-1 Month Momentum % | -77.47 | ||
| 52-Week Range ($) | 0.7966 - 6.8 | ||
| Shares Outstanding (Mil) | 55.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Prelude Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Prelude Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Prelude Therapeutics Inc Frequently Asked Questions
What is Prelude Therapeutics Inc(PRLD)'s stock price today?
The current price of PRLD is $1.19. The 52 week high of PRLD is $6.80 and 52 week low is $0.80.
When is next earnings date of Prelude Therapeutics Inc(PRLD)?
The next earnings date of Prelude Therapeutics Inc(PRLD) is 2025-02-14 Est..
Does Prelude Therapeutics Inc(PRLD) pay dividends? If so, how much?
Prelude Therapeutics Inc(PRLD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers